Submitted by Marlene Santos (marlene.bc.ufg@gmail.com) on 2014-09-30T18:51:57Z
No. of bitstreams: 2
Dissertação- Maria Helena Tavares Vilela-2013.pdf: 2276556 bytes, checksum: 772ad6ab585b17765e734a42bc50eb7e (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Jaqueline Silva (jtas29@gmail.com) on 2014-09-30T19:29:06Z (GMT) No. of bitstreams: 2
Dissertação- Maria Helena Tavares Vilela-2013.pdf: 2276556 bytes, checksum: 772ad6ab585b17765e734a42bc50eb7e (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2014-09-30T19:29:06Z (GMT). No. of bitstreams: 2
Dissertação- Maria Helena Tavares Vilela-2013.pdf: 2276556 bytes, checksum: 772ad6ab585b17765e734a42bc50eb7e (MD5)
license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)
Previous issue date: 2013-10-09 / The proper management of breast phyllodes tumors (PTs) remains challenging, due to the difficulty of the correct preoperative diagnosis. The aim of this study was to evaluate the usefulness of the Ki-67, CD10, CD34, p53, CD117 and the number of mast cells for the differential diagnosis between benign PTs and cellular fibroadenomas (CFs), and also at the
grading of PTs. 51 primary PTs and 14 FCs were examined by immunohistochemistry (IH). Through the evaluation of the expression of CD117, greater epithelial expression was found at the FCs and an increased number of mast cells in benign TFs. The stromal expression of the Ki-67, CD10, CD34 and p53 showed relevance to the grading of PTs. / O manejo adequado dos tumores filóides (TFs) mamários continua desafiador, devido à dificuldade do diagnóstico pré-operatório correto. O objetivo deste estudo foi avaliar a utilidade do Ki-67, do CD34, do CD10, do CD117, da p53 e do número de mastócitos no diagnóstico diferencial entre os TFs benignos e fibroadenomas celulares (FCs), bem como na graduação dos TFs. Foram examinados 51 TFs primários e 14 FCs por imunohistoquímica (IH). Na marcação pelo CD117, houve maior expressão epitelial nos FCs e maior número de mastócitos nos TFs benignos. A expressão estromal do Ki-67, da p53, do CD10 e CD34 mostrou-se significante na graduação dosTFs.
Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.bc.ufg.br:tede/3229 |
Date | 09 October 2013 |
Creators | Vilela, Maria Helena Tavares |
Contributors | Moreira, Marise Amaral Rebouças, Moreira, Marise Amaral Rebouças, Paulinelli, Régis Resende, Deus, José Miguel, Finotti, Marta Curado Carvalho Franco |
Publisher | Universidade Federal de Goiás, Programa de Pós-graduação em Ciências da Saúde (FM), UFG, Brasil, Faculdade de Medicina - FM (RG) |
Source Sets | IBICT Brazilian ETDs |
Language | Portuguese |
Detected Language | English |
Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
Format | application/pdf |
Source | reponame:Biblioteca Digital de Teses e Dissertações da UFG, instname:Universidade Federal de Goiás, instacron:UFG |
Rights | http://creativecommons.org/licenses/by-nc-nd/4.0/, info:eu-repo/semantics/openAccess |
Relation | -1006864312617745310, 600, 600, 600, 1545772475950486338, 7337577453819502453, 1. Tan PH, Tse G, Lee H, Simpson JF, Hanby AM. WHO Classification of Tumours of the Breast. 4° ed. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, M.J. vdV, editors. Lyon: IARC; 2012. 2. Tan PH, Jayabaskar T, Chuah KL, Lee HY, Tan Y, Hilmy M, Hung H, Selvarajan S, Bay BH. Phyllodes tumors of the breast: the role of pathologic parameters. Am J Clin Pathol. 2005; 123(4):529-40. 3. Chaney AW, Pollack A, McNeese MD, Zagars GK, Pisters PW, Pollock RE, Hunt KK. Primary treatment of cystosarcoma phyllodes of the breast. Cancer. 2000;89(7):1502-11. en. 4. Moffat CJ, Pinder SE, Dixon AR, Elston CW, Blamey RW, Ellis IO. Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. Histopathology. 1995 Sep;27(3):205-18. 5. Lenhard MS, Kahlert S, Himsl I, Ditsch N, Untch M, Bauerfeind I. Phyllodes tumour of the breast: Clinical follow-up of 33 cases of this rare disease. European Journal of Obstetrics Gynecology and Reproductive Biology. 2008;138(2):217-21. 6. Foxcroft LM, Evans EB, Porter AJ. Difficulties in the pre-operative diagnosis of phyllodes tumours of the breast: a study of 84 cases. Breast. 2007 Feb;16(1):27-37. 7. Ward ST, Jewkes AJ, Jones BG, Chaudhri S, Hejmadi RK, Ismail T, Hallissey MT. The sensitivity of needle core biopsy in combination with other investigations for the diagnosis of phyllodes tumours of the breast. International journal of surgery. 2012;10(9):527-31. 8. Jacklin RK, Ridgway PF, Ziprin P, Healy V, Hadjiminas D, Darzi A. Optimising preoperative diagnosis in phyllodes tumour of the breast. Journal of clinical pathology. 2006 May;59(5):454-9. 9. Tan PH, Thike AA, Tan WJ, Thu MM, Busmanis I, Li H, Chay WY, Tan MH, Phyllodes Tumour Network S. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. Journal of clinical pathology. 2012 Jan;65(1):69-76. 10. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ. Phyllodes tumor: A clinicopathologic and immunohistochemical study of 30 cases. Archives of Pathology and Laboratory Medicine. 2006;130(10):1516-21. 11. Noronha Y, Raza A, Hutchins B, Chase D, Garberoglio C, Chu P, Weiss L, Wang J. CD34, CD117, and Ki-67 expression in phyllodes tumor of the breast: an immunohistochemical study of 33 cases. International journal of surgical pathology. 2011 Apr;19(2):152-8. 12. Tan PH, Jayabaskar T, Yip G, Tan Y, Hilmy M, Selvarajan S, Bay BH. P53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: A tissue microarray study. Modern Pathology. 2005;18(12):1527-34. 13. Korcheva VB, Levine J, Beadling C, Warrick A, Countryman G, Olson NR, Heinrich MC, Corless CL, Troxell ML. Immunohistochemical and molecular markers in breast phyllodes tumors. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 2011 Mar;19(2):11925 14. Carvalho S, Silva A O, Milanezi F, Ricardo S, Leitão D, Amendoeira I, Schmitt F C. cKIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? Journal of clinical Pathology.2004; 57 (10): 1075-9 15. Kim J, Kim R, Kim K, Jung Y, Soh E, Yim H, Chun M. Correlation of CD10 and EGFR expression in phyllodes tumors of the breast. European Journal of Cancer. 2012;48:S122-S3. 16. Ibrahim WS. Comparison of stromal CD10 expression in benign, borderline, and malignant phyllodes tumors among Egyptian female patients. Indian Journal of Pathology and Microbiology. 2011;54(4):741-4. 17. Ho SK, Thike AA, Cheok PY, Tse GM, Tan PH. Phyllodes tumours of the breast: the role of CD34, vascular endothelial growth factor and beta-catenin in histological grading and clinical outcome. Histopathology. 2013 May 7. 18. Jiang L, Hua Y, Shen Q, Ding S, Jiang W, Zhang W, Zhu X. Role of mast cells in gynecological neoplasms. Frontiers in bioscience : a journal and virtual library. 2013;18:77381. 19. Amini RM, Aaltonen K, Nevanlinna H, Carvalho R, Salonen L, Heikkila P, Blomqvist C. Mast cells and eosinophils in invasive breast carcinoma. BMC cancer. 2007;7:165. 20. Djordjevic B, Hanna WM. Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon. Mod Pathol. 2008 Oct;21(10):1238-45. 21. Ilic I, Randelovic P, Ilic R, Katic V, Milentijevic M, Velickovic L, Krstic M. An approach to malignant mammary phyllodes tumors detection. Vojnosanitetski pregled Militarymedical and pharmaceutical review. 2009 Apr;66(4):277-82. 22. Tavassoli FA, Eusebi V. Tumors of the Mammary Gland. Washington, DC: American Registry of Pathology; 2009 2009. 0-418 p. 23. Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, Lee CS. p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. Histopathology. 2010 Jun;56(7):868-75 24. Tse GM, Putti TC, Kung FY, Scolyer RA, Law BK, Lau TS, Lee CS. Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol. 2002 2002/07/;15(7):734-40. 25. Yonemori K, Hasegawa T, Shimizu C, Shibata T, Matsumoto K, Kouno T, Ando M, Katsumata N, Fujiwara Y. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. Pathology, research and practice. 2006;202(10):705-12. 26. Chan YJ, Chen BF, Chang CL, Yang TL, Fan CC. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast. Journal of the Chinese Medical Association : JCMA. 2004 Jan;67(1):3-8. 27. Jones AM, Mitter R, Springall R, Graham T, Winter E, Gillett C, Hanby AM, Tomlinson IP, Sawyer EJ, Phyllodes Tumour C. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence. The Journal of pathology. 2008 Apr;214(5):533-44. 28. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001 Aug 2;20(34):4621-8. 29. Hainaut P, Eeles R, Ohgaki H, Olivier M. Li-Fraumeni Syndrome. In: Tavassoli FA, Devilee P, editors. Tumours of the Breast and Female Organs. Lyon: IARCPress; 2003. p. 351-4. 30. Tse GM, Tsang AK, Putti TC, Scolyer RA, Lui PC, Law BK, Karim RZ, Lee CS. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. Journal of clinical pathology. 2005 Feb;58(2):185-9. 31. Al-Masri M, Darwazeh G, Sawalhi S, Mughrabi A, Sughayer M, Al-Shatti M. Phyllodes tumor of the breast: role of CD10 in predicting metastasis. Annals of surgical oncology. 2012 Apr;19(4):1181-4. 32. Kim GE, Kim JH, Lee KH, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Park MH, Yoon JH. Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. 2012 May;20(3):298-303. 33. Moore T, Lee AH. Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. Histopathology. 2001 Jan;38(1):62-7. 34. Logullo AF, Nonogaki S, Do Socorro Maciel M, Mourao-Neto M, Soares FA. Stromal and epithelial cells react differentially to c-kit in fibroepithelial tumors of the breast. Molecular medicine reports. 2008 Nov-Dec;1(6):857-61. 35. Kacar A, Paker I, Akbiyik F, Arikok AT, Mambet E. CD117 and CD34 staining patterns in childhood benign mammary lesions. Turk Patoloji Derg. 2012;28(1):31-7. 36. Yared MA, Middleton LP, Meric F, Cristofanilli M, Sahin AA. Expression of c-kit proto-oncogene product in breast tissue. Breast J. 2004 Jul-Aug;10(4):323-7. |
Page generated in 0.0048 seconds